Biogen

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1978-01-01

Employees: 7.5K

Market Cap: $29.6B

Website: https://www.biogen.com

Introduction: Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Clinical Trials

An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Phase 3

Completed

Conditions: Relapsing-Remitting Multiple Sclerosis
Multiple Sclerosis

Interventions: Drug: Placebo
Drug: dimethyl fumarate

First Posted Date: 2013-04-24

Last Posted Date: 2018-11-20

Lead Sponsor: Biogen

Target Recruit Count: 225

Registration Number: NCT01838668

Locations: 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇵🇱
Miedzyleski Szpital Specjalistyczny, Warszawa, Poland
🇵🇱
Nzoz Novo-Med, Katowice, Poland

and more 51 locations

Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019

Phase 3

Terminated

Conditions: Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis

Interventions: Drug: BIIB019 (Daclizumab)

First Posted Date: 2013-02-25

Last Posted Date: 2019-12-04

Lead Sponsor: Biogen

Target Recruit Count: 1501

Registration Number: NCT01797965

Locations: 🇬🇧
Research Site, Sheffield, United Kingdom

An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1 (NCT01494701)

Phase 1

Completed

Conditions: Spinal Muscular Atrophy

Interventions: Drug: nusinersen

First Posted Date: 2013-01-31

Last Posted Date: 2021-02-16

Lead Sponsor: Biogen

Target Recruit Count: 18

Registration Number: NCT01780246

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
University of Utah School of Medicine, Salt Lake City, Utah, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States

and more 1 locations

A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: PF-04958242
Drug: Placebo
Drug: Ketamine

First Posted Date: 2012-12-13

Last Posted Date: 2019-11-21

Lead Sponsor: Biogen

Target Recruit Count: 29

Registration Number: NCT01749098

Locations: 🇺🇸
Pfizer Investigational Site, West Haven, Connecticut, United States

Functional MRI in Lupus Nephritis

Completed

Conditions: Lupus Nephritis
Healthy

First Posted Date: 2012-11-21

Last Posted Date: 2015-04-27

Lead Sponsor: Biogen

Target Recruit Count: 50

Registration Number: NCT01731054

Locations: 🇺🇸
Research Site, Columbus, Ohio, United States

BIIB033 In Acute Optic Neuritis (AON)

Phase 2

Completed

Conditions: Acute Optic Neuritis

Interventions: Biological: BIIB033 (anti-LINGO-1 mAb)
Drug: Placebo

First Posted Date: 2012-11-04

Last Posted Date: 2016-06-30

Lead Sponsor: Biogen

Target Recruit Count: 82

Registration Number: NCT01721161

Locations: 🇮🇹
Research site, Roma, Italy
🇬🇧
Research Site, London, United Kingdom

Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants

Terminated

Conditions: Relapsing-Remitting Multiple Sclerosis

First Posted Date: 2012-10-15

Last Posted Date: 2024-06-03

Lead Sponsor: Biogen

Target Recruit Count: 73

Registration Number: NCT01706107

Locations: 🇨🇦
CHUS - Hopital Fleurimont, Sherbrooke, Quebec, Canada
🇨🇦
Cape Breton Regional Hospital, Sydney, Nova Scotia, Canada
🇨🇦
CHUM - Hopital Notre Dame, Montreal, Quebec, Canada

and more 8 locations

An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy

Phase 1

Completed

Conditions: Spinal Muscular Atrophy

Interventions: Drug: Nusinersen

First Posted Date: 2012-10-11

Last Posted Date: 2021-04-13

Lead Sponsor: Biogen

Target Recruit Count: 34

Registration Number: NCT01703988

Locations: 🇺🇸
University of Utah School of Medicine, Salt Lake City, Utah, United States
🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
UT Southwestern Medical Center - Children's Medical Center Dallas, Dallas, Texas, United States

and more 1 locations

Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease

Phase 1

Terminated

Conditions: Alzheimer's Disease

Interventions: Drug: Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb)
Drug: Placebo

First Posted Date: 2012-09-03

Last Posted Date: 2020-08-03

Lead Sponsor: Biogen

Target Recruit Count: 197

Registration Number: NCT01677572

Locations: 🇺🇸
Infinity Clinical Research, Inc., Sunrise, Florida, United States
🇺🇸
Senior Clinical Trials, Inc., Laguna Hills, California, United States
🇺🇸
University of California, Los Angeles, Los Angeles, California, United States

and more 29 locations

BIIB057 in Subjects With Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs

Phase 2

Withdrawn

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: BIIB057

First Posted Date: 2012-07-30

Last Posted Date: 2013-09-16

Lead Sponsor: Biogen

Registration Number: NCT01652937

Locations: 🇨🇦
Research Site, Toronto, Ontario, Canada

Home Terms & Conditions Privacy Policy